CMPX
Compass Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -12.5% ·
share flow -30.0% ·
net new positions -14.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +4 | 68.60M | $150.73M | +11 | −7 |
| Q1 2026 | 79 | +9 | 59.45M | $314.31M | +12 | −3 |
| Q4 2025 | 70 | +2 | 49.56M | $266.12M | +3 | −1 |
| Q3 2025 | 15 | 0 | 39.02M | $136.56M | +1 | −1 |
| Q2 2025 | 12 | +1 | 25.65M | $66.69M | +1 | — |
| Q1 2025 | 8 | +1 | 9.48M | $18.01M | +1 | — |
| Q4 2024 | 7 | -1 | 10.74M | $15.57M | — | −1 |
| Q3 2024 | 7 | -1 | 14.12M | $25.99M | — | −1 |
| Q2 2024 | 8 | — | 14.75M | $14.75M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 5.99M | -46.1% | $8.69M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.33M | +1.1% | $3.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 1.90M | — | $2.76M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 278.60K | +25.2% | $403,970 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 145.24K | -24.9% | $210,595 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 46.94K | +31.8% | $69,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 33.86K | -80.0% | $49,093 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $118,176 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 199 holders, 172.39M shares, $913.59M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · Chief Accounting… · 20.00K sh @ 0.92 · $18,400
Officer · Chief Accounting… · 2.50K sh @ 1.14 · $2,850
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology